CABA Stock Summary and Trading Ideas (Cabaletta Bio | NASDAQ:CABA)

Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.

Cabaletta Bio trades on the NASDAQ stock market under the symbol CABA.

As of November 10, 2026, CABA stock price declined to $1.43 with 2,330,168 million shares trading.

CABA has a beta of 2.43, meaning it tends to be more sensitive to market movements. CABA has a correlation of 0.11 to the broad based SPY ETF.

CABA has a market cap of $242.45 million. This is considered a Small Cap stock.

In the last 3 years, CABA traded as high as $26.35 and as low as $.99.

The top ETF exchange traded funds that CABA belongs to (by Net Assets): VTI, XBI, IWM, VXF, FESM.

CABA has underperformed the market in the last year with a return of -43.9%, while the SPY ETF gained +12.8%. In the last 3 month period, CABA fell short of the market, returning -48.7%, while SPY returned -2.8%. However, in the most recent 2 weeks CABA has outperformed the stock market by returning +5.9%, while SPY returned -2.1%.

CABA support price is $1.41 and resistance is $1.59 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CABA shares will trade within this expected range on the day.